Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 8/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631373 | 0.89 | YTHDC1 (0.50) | YTHDC1HDAC6HDAC1HDAC4HDAC3 | |
| SCHEMBL822875 | 0.87 | PDE8A (0.56) | YTHDC1 | |
| SCHEMBL5465713 | 0.84 | P2RX7 (0.56) | YTHDC1HDAC6HDAC1HDAC4HDAC3 | |
| SCHEMBL5461215 | 0.82 | HDAC6 (0.60) | YTHDC1HDAC6HDAC1HDAC4HDAC3 | |
| SCHEMBL13596788 | 0.82 | HDAC6 (0.57) | YTHDC1HDAC6HDAC1HDAC4HDAC3 | |
| SCHEMBL5459615 | 0.82 | HDAC6 (0.60) | YTHDC1HDAC6HDAC1HDAC4HDAC3 | |
| SCHEMBL183057 | 0.81 | YTHDC1 (0.68) | YTHDC1HDAC1HDAC2HDAC8P2RX7 | |
| SCHEMBL30898278 | 0.81 | YTHDC1 (0.68) | YTHDC1HDAC1HDAC2HDAC8P2RX7 | |
| SCHEMBL30677470 | 0.80 | P2RX7 (0.60) | YTHDC1HDAC6HDAC1HDAC4HDAC3 | |
| SCHEMBL15315258 | 0.80 | YTHDC1 (0.46) | YTHDC1HDAC6HDAC1HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| EP-2563404-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2016-09-21 | — | — | EP | disclosed |
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| EP-1931352-B1 | TLR AGONISTS | UNIV CALIFORNIA (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2016-03-31 | — | — | US | disclosed |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2016-03-31 | — | — | US | disclosed |
| CN-101790380-A | The conjugate and the application thereof of synthetic TLR agonist | UNIV CALIFORNIA | 2010-07-28 | — | — | CN | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2125007-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | Regents of the University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101304748-A | Tlr agonists | UNIV CALIFORNIA (US) | 2008-11-12 | — | — | CN | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1931352-A2 | TLR AGONISTS | The Regents of the University of California Office of Technology Transfer (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324551-A1 | TLR AGONISTS | TLR3, TLR1, TLR5 | YTHDC1 3900/4885HDAC6 263/4885HDAC1 2269/4885 |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | YTHDC1 4672/4885HDAC6 1462/4885HDAC1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.